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Overview 
Testing of specimens within the United States to determine possible Zika virus infection should be limited to 
specimens collected from patients meeting CDC’s clinical and epidemiological criteria for testing1. Clinical signs 
and symptoms associated with Zika virus infection are discussed here: 
http://www.cdc.gov/zika/symptoms/index.html.  It is important to note that Zika virus infection can cause signs 
and symptoms similar to those seen in patients with dengue and chikungunya virus infections.   
Current information and guidance for the U.S. Zika response is available on CDC’s Zika website:  
http://www.cdc.gov/zika/index.html.  Information specific to state and public health laboratory response:  
http://www.cdc.gov/zika/laboratories/index.html.  
Full testing algorithms are presented at the end of this document. 
NOTE:  Serum and urine are the primary diagnostic specimens for Zika virus infection.   
Symptomatic individuals meeting epidemiological criteria: 
Serum and urine collected from symptomatic patients < 14 days post onset of symptoms (DPO) should 
be tested by Zika virus real time reverse transcriptase-polymerase chain reaction (rRT-PCR).  A positive 
                                                          
1 The term “clinical and epidemiological critera” refers to factors such as symptoms, pregnancy and exposure risk.  Please 
refer to current CDC clinical guidance: http://www.cdc.gov/zika/hc-providers/index.html 
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Zika rRT-PCR result in either specimen is sufficient to diagnose Zika virus infection.  If Zika virus rRT-PCR 
results are negative for both specimens, serum should be tested by antibody detection methods. 
Serum that has been collected from patients presenting 2-12 weeks from onset of symptoms should be 
tested first by anti-Zika immunoglobulin (IgM) detection methods.  Serum from symptomatic pregnant 
women should also be accompanied by a urine specimen. 
 For non-pregnant symptomatic patients, anti-Zika IgM positive or equivocal result is followed by 
plaque reduction neutralization test (PRNT) directly. 
 For symptomatic pregnant women, anti-Zika IgM positive or equivocal result is followed by rRT-
PCR on both serum and urine.  Some pregnant women have been reported to have detectable 
RNA present in serum and/or urine beyond the acute phase.  If the rRT-PCR is negative, PRNT is 
necessary to confirm the presence of anti-Zika antibodies.   
Asymptomatic pregnant women meeting epidemiological criteria for testing: 
If serum and urine have been collected from a pregnant woman presenting within 2 weeks of her 
exposure or living in areas of ongoing transmission, serum and urine should be tested by rRT-PCR.  If 
negative, a second serum specimen should be collected 2-12 weeks following return from travel and 
tested by antibody detection methods.  
If serum from a pregnant woman first presenting 2-12 weeks following exposure is collected, the serum 
should be tested for anti-Zika IgM.  If positive or equivocal, rRT-PCR should be performed on the serum 
and urine.  If rRT-PCR is negative, PRNT should be performed for confirmation of IgM result. 
 
A note on testing of other specimen types: 
If testing of cerebrospinal fluid (CSF) from a symptomatic individual is requested for clinically indicated 
reasons (e.g., neurological symptoms), the specimen(s) must be submitted alongside a patient-matched 
serum specimen.  A Zika virus rRT-PCR positive result from any specimen is indicative of Zika virus 
infection.   
 Amniotic fluid testing  by rRT-PCR may be considered following onset of symptoms in a pregnant 
woman; the optimal time to perform amniocentesis is unknown, however, amniocentesis 
performed ≥15 weeks of gestation is associated with lower rates of complications than those 
performed at earlier gestational ages, and early amniocentesis (≤14 weeks of gestation) is not 
recommended  
 CSF should be tested by rRT-PCR if collected within the first week following onset or by antibody 
detection methods if collected after day 7 post onset of symptoms.   
The patient-matched serum (and urine) submitted alongside these specimens should be tested 
according to the method(s) recommended for the time point post-onset indicated in the algorithms 
below. 
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Specimen Referral 
Health care and laboratory professionals are instructed to direct Zika virus testing requests to their local or state 
public health laboratory or to a commercial laboratory that performs Zika testing using a validated assay with 
demonstrated analytical and clinical performance. Health care and laboratory professionals should follow state 
or local public health department guidance on notification procedures for suspect cases of Zika virus infection. 
Public health laboratories that are not CDC-designated Zika virus testing laboratories should work with their 
state or territorial public health department for testing of suspect specimens or referring specimens to CDC.   
Within the 50 states, information about submitting specimens to CDC is at: 
http://www.cdc.gov/ncezid/dvbd/specimensub/arboviral-shipping.html.   
Within Puerto Rico, please call 787-706-2399 for questions about testing. For submission of specimens, please 
submit a dengue case investigation report (DCIR) for each specimen, which can be downloaded from: 
http://www.cdc.gov/dengue/clinicalLab/index.html 
Specimen Type 
Serum and urine are the preferred specimens for laboratory diagnosis of Zika virus infection. 
Collection of specimens should be conducted using standard precautions for blood-borne pathogens. 
Guidance for collection storage and transport of body fluid specimens in provided at the following link: 
http://www.cdc.gov/zika/laboratories/test-specimens-bodyfluids.html.  
Serum  
Serum must be submitted for all patients to be tested for Zika virus infection.  Serum may be tested by 
both antibody detection and molecular methods for Zika, dengue, and chikungunya (see algorithm on 
following pages for clarification).  RNA from Zika, dengue, and chikungunya viruses is generally 
detectable in serum during the acute phase of infection).  There is limited evidence suggesting some 
patients may have RNA detectible in serum and/or urine for a longer period of time (Bingham et al., 
2016).  Levels of anti-Zika IgM antibodies in infected individuals typically rise shortly after symptom 
onset and persist for 8-12 weeks. 
 
NOTE: Serum should be collected in serum separator tubes and centrifuged to prevent hemolysis.  
Serum should then be decanted into a plastic vial for transport as described in the CDC guidance for 
collection and transport. 
 
Urine 
Urine should be tested alongside a patient-matched serum specimen by molecular methods for Zika 
virus only if the method has been validated for this specimen type.    Antibody testing of urine is not 
recommended.  
 
There is some limited evidence that Zika virus RNA may be detectable in urine for a longer period of 
time than in serum.  Thus, CDC recommends that urine be collected alongside serum from symptomatic 
patients presenting up to 14 days post onset of symptoms and from asymptomatic pregnant women.  
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The patient-matched serum specimen should be tested using the recommended serum testing 
method(s) for the specimen collection time point post onset of symptoms. 
 
NOTE: Please do not submit urine in urine collection cups for Zika virus testing.  Urine should be 
transferred to a clean vial with screw cap and O-ring to prevent leakage in transport. 
 
Other Specimen Types 
Note: When testing of other specimen types is indicated, these specimens must be submitted alongside 
a patient-matched serum specimen.   
 
CSF 
CSF may be tested alongside a patient-matched serum specimen by both antibody detection and 




Amniotic fluid may be tested alongside a patient-matched serum (and urine) specimens by molecular 
methods for Zika virus if the specimen type has been validated in the assay. 
 
Molecular testing of amniotic fluid for the presence of Zika virus RNA can be requested following onset 
of symptoms in a pregnant woman as clinically indicated.  The patient-matched serum and urine 
specimens should be tested using the recommended testing method(s) for the time point post onset of 
symptoms. 
 
 Tissue Specimens 
Zika, dengue, and chikungunya virus testing on fixed and frozen tissue is available at CDC.  Requests for 
testing should be coordinated through your state or local health department.  Additional information 
about specimen collection and submission procedures is available on CDC’s website: 
http://www.cdc.gov/zika/laboratories/test-specimens-tissues.html.  
Use of CDC Assays by Qualified Laboratories  
The CDC Trioplex rRT-PCR and Zika MAC-ELISA (testing for anti-Zika IgM) are available to qualified laboratories in 
the United States.  Eligible public health laboratories are those who have demonstrated proficiency with ELISA-
based serological methods (for CDC Zika MAC-ELISA) or with rRT-PCR (for CDC Trioplex rRT-PCR) and who have 
facilities, personnel and equipment appropriate to the safe handling of specimens suspected of containing Zika, 
dengue, or chikungunya viruses.  State, local, and territorial public health departments interested in obtaining 
the materials described above should contact LRN@cdc.gov for an application. 
CDC-designated laboratories who perform the CDC Zika MAC-ELISA and/or Trioplex rRT-PCR are first required to 
demonstrate proficiency with the assay(s) by successfully testing verification panels for each assay.  Only labs 
that have been notified by CDC that they have successfully completed the verification testing are authorized to 
use the CDC assays for diagnostic testing. 
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Biological Safety 
Please review CDC Biosafety Guidance for Transportation of Specimens and for Work with Zika Virus in the 
Laboratory: http://www.cdc.gov/zika/laboratories/lab-safety.html. See the Biosafety in Microbiological and 
Biomedical Laboratories (BMBL) for additional biosafety information about these viruses and laboratory 
biosafety practices: http://www.cdc.gov/biosafety/publications/bmbl5/index.htm. 
Methods 
Molecular testing 
Detection of Zika virus RNA in serum and in urine collected from symptomatic individuals can be an 
effective aid to diagnose a recent Zika virus infection.  CDC recommends the use of the FDA-authorized 
Trioplex Real-time RT-PCR Assay (Trioplex rRT-PCR) for detection of Zika, dengue, and chikungunya viral 
RNA in specimens collected from individuals suspected of Zika infection and meeting CDC clinical and 
epidemiological criteria.   
Serum:  Zika virus is usually detected in serum during the acute phase of infection.  Due to the difficulty 
in many cases of precisely determining the onset date of symptoms, as well as the general low 
level of Zika viremia in serum, all rRT-PCR negative serum specimens should be tested by 
serological methods as well. 
Urine:  Zika virus RNA has been detected in urine for a longer period of time than in serum (Bingham et 
al., 2016).  Based on a limited number of cases, detection of Zika virus RNA has been 
demonstrated up to 14 days after onset of symptoms.  Beyond 14 days, urine testing may still be 
useful, but there are limited data to determine Zika virus RNA persistence in urine.  CDC 
recommends that, for symptomatic individuals presenting up to 14 days after onset of 
symptoms, urine be collected alongside serum and be tested by rRT-PCR (MMWR, 2016).  
If clinically indicated, CSF and amniotic fluid may be tested by rRT-PCR alongside a patient-matched 
serum specimen. 






FDA-authorized kit (EUA):  
CDC Trioplex rRT-PCR  
Zika RNA 
only* 
FDA-authorized kit (EUA): commercial laboratories 
Focus Diagnostics Zika Virus RNA Qualitative Real-Time RT-PCR 
altona RealStar Zika Virus RT-PCR   
Hologic Aptima Zika Virus Assay (transcription-mediated 
amplification TMA test) 
 
Dengue RNA  
only 
FDA-cleared kit: 
CDC DENV-1-4 Real-Time RT-PCR Assay  
*FDA maintains a list of all Zika virus Emergency Use Authorizations on their website.  Please refer to their 
website for the current list of the assays and the associated letters of authorization, fact sheets and product 
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labeling. Assay-specific information (e.g., acceptable specimen types, performance characteristics) is included in 
the labeling.  http://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm 
Co-infection is rare, but possible and should be considered in patients whose specimens generate 
positive results for more than one of these viruses.   It is important to note that a positive result for one 
of these viruses does not preclude infection with the others. 
Antibody detection methods 
NOTE: If Zika rRT-PCR testing was conducted for a patient and any of the patient’s specimens yielded 
positive results, the patient is positive for Zika infection.  No antibody testing is required. Refer to 
algorithms at the end of this document. 
Because of the potential for cross-reactivity, all serum specimens obtained from symptomatic 
individuals for whom serological testing is recommended should be tested with IgM antibody capture 
methods for the detection of anti-Zika IgM, and anti-dengue IgM.  For those with exposure risk and a 
clinically compatible illness2, anti-chikungunya IgM testing should also be performed.   




FDA-authorized kit (EUA): 




DENV Detect IgM Capture ELISA (InBiOS, USA) 
Commercial laboratories with capability: 
Focus Diagnostics (http://www.focusdx.com/)  
ARUP Laboratories (http://www.aruplab.com/)  




Commercial laboratories with capability: 
Focus Diagnostics (http://www.focusdx.com/)  
ARUP Laboratories (http://www.aruplab.com/)  
*FDA maintains a list of all Zika virus Emergency Use Authorizations on their website.  Please refer to their 
website for the current list of the assays and the associated letters of authorization, fact sheets and product 
labeling. Assay-specific information (e.g., acceptable specimen types, performance characteristics) is included in 
the labeling.  http://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm 
Confirmation of antibody results 
Confirmation of positive and equivocal IgM results is necessary and should be conducted according to 
the attached algorithm.  If PRNT testing is indicated, that testing must be conducted by CDC or by a 
PRNT laboratory designated by CDC to do confirmatory PRNT testing for the Zika response. 
Confirmation of anti-chikungunya IgM positive and equivocal results by PRNT: 
                                                          
2 Clinical information about chikungunya virus infection, including clinical evaluation guidance, may be found on CDC’s 
website: www.cdc.gov/chikungunya/hc/index.html 
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Confirmation of anti-chikungunya virus IgM assay results should be conducted by PRNT using 
chikungunya virus.   
 If no neutralization is observed (PRNT titer to chikungunya virus <10), the specimen is 
negative for evidence of recent chikungunya virus infection.   
 If neutralization is observed (PRNT titer to chikungunya virus ≥ 10), the specimen is 
positive for evidence of recent chikungunya virus infection. 
Confirmation of anti-Zika IgM positive and equivocal results and anti-dengue IgM positive and equivocal 
results by PRNT: 
When rRT-PCR testing is not positive, anti-Zika IgM presumptive positive and equivocal results 
require confirmation by PRNT.  It should be noted, however, that if a patient has a positive rRT-
PCR result for the virus whose IgM assay gave a positive or equivocal result, no PRNT 
confirmation of the IgM result is necessary.  A positive rRT-PCR result for a patient is a definitive 
indication of infection. 
While no false negative results with the Zika MAC-ELISA have been detected during assay 
evaluation, there has been demonstrated cross-reactivity to anti-dengue virus IgM, and some 
false positive results in specimens with no detectable neutralizing flavivirus antibodies (by PRNT) 
upon confirmation.  
PRNT may not be able to provide definitive determination of the specific virus causing the 
recent infection, particularly in individuals with a history of previous flavivirus infection.   
Results of Zika/dengue PRNT testing should be interpreted alongside IgM assay results to come 
to an overall determination, as described in the following table reproduced from the CDC 
Interim Guidance for Interpretation of Zika Virus Antibody Results (Rabe et al., 2016).  Please 
note that recommended time frame for testing of serum by rRT-PCR has changed since 
publication and has been updated in the table’s footnote. 
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Interpretation of results of antibody testing for suspected Zika virus infection*,†,§,¶,** - United States, 2016 
Zika virus and dengue virus IgM ELISA Zika virus PRNT Dengue virus PRNT Interpretation 
Positive or equivocal (either assay) ≥10 <10 Recent Zika virus infection† 
Positive or equivocal (either assay) <10 ≥10 Recent dengue virus infection† 
Positive or equivocal (either assay) ≥10 ≥10 Recent flavivirus infection; specific virus 
cannot be identified† 
Any result (either or both assays) <10 <10 No evidence of Zika virus or dengue virus 
infection 
Inconclusive in one assay AND inconclusive or negative 
in the other 
≥10 <10 Evidence of Zika virus infection; timing cannot 
be determined§ 
Inconclusive in one assay AND inconclusive or negative 
in the other 
<10 ≥10 Evidence of dengue virus infection; timing 
cannot be determined§ 
Inconclusive in one assay AND inconclusive or negative 
in the other 
≥10 ≥10 Evidence of flavivirus infection; specific virus 
and timing cannot be determined§ 
Positive for Zika virus AND negative for dengue virus Not yet performed Presumptive recent Zika virus infection†,§ 
Positive for dengue virus AND negative for Zika virus Not yet performed Presumptive recent dengue virus infection†,§ 
Positive for Zika virus AND positive for dengue virus Not yet performed Presumptive recent flavivirus virus infection†,§ 
Equivocal (either or both assays) Not yet performed Equivocal results§ 
Inconclusive (either or both assays) Not yet performed Inconclusive results§ 
Negative for Zika virus AND negative for dengue virus Not indicated No evidence of recent Zika virus or dengue 
virus infection 
*For persons with suspected Zika virus disease, Zika virus real-time reverse transcription–polymerase chain reaction (rRT-PCR) should be performed on 
serum and urine specimens collected <14 days after onset of symptoms.  
†In the absence of rRT-PCR testing, negative IgM or neutralizing antibody testing in specimens collected <7 days after illness onset might reflect collection 
before development of detectable antibodies and does not rule out infection with the virus for which testing was conducted. 
§Zika IgM positive result is reported as “presumptive positive” to denote the need to perform confirmatory PRNT. 
¶Report any positive or equivocal IgM Zika or dengue results to state or local health department. 
**To resolve false-positive results that might be caused by cross-reactivity or nonspecific reactivity, presumptive positive Zika IgM results should be 
confirmed with PRNT titers against Zika, dengue, and other flaviviruses to which the person might have been exposed. In addition, equivocal and 
inconclusive results that are not resolved by retesting also should have PRNT titers performed to rule out a false-positive result. 
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Reporting 
Each test result generated for each specimen should be reported as specified in the assay instructions for use.  
Results generated by methods used under FDA Emergency Use Authorization (EUA) must be accompanied by 
the appropriate Fact Sheets when reported back to providers and patients.  Fact Sheets have been prepared for 
health care providers, patients and pregnant women to help each understand the results of testing.  Authorized 
fact sheets for each assay under EUA are posted to the FDA website: 
http://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm 
Tables and algorithms in this document are intended to assist labs in combining results from multiple 
specimens/methods to make appropriate decisions about next testing steps.   
Guidance documents are available to assist in applying lab results to determine patient care and patient follow-
up decisions:  
Zika clinical guidance for health care providers caring for pregnant women, women of reproductive age, 
infants, children or other symptomatic individuals: 
http://www.cdc.gov/zika/hc-providers/index.html 
Dengue clinical guidance: 
http://www.cdc.gov/dengue/clinicalLab/index.html 
Chikungunya clinical guidance: 
http://www.cdc.gov/chikungunya/hc/index.html 
Please note that Zika, dengue and chikungunya virus infections are all on the 2016 list of nationally notifiable 
conditions: https://wwwn.cdc.gov/nndss/conditions/notifiable/2016/. Therefore, results of testing should be 
reported back to state or local health department staff to facilitate investigation and classification of the case 
and reporting to CDC. 
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2016 Zika Response: Algorithm for U.S. Testing of Symptomatic Individuals* 
Specimens Collected <14 days Following Symptom Onset  
 
*Pregnant and non-pregnant symptomatic individuals 
**For CDC guidance on patient management and follow-up for dengue or chikungunya virus infection, please refer to the CDC websites listed on p. 9 of this 
document. 
Serum and Urine Specimens Received 
(possibly with CSF or amniotic fluid) 
Test all specimens by rRT-PCR 
Note: Urine and amniotic fluid are not acceptable 
specimen types for dengue and chikungunya rRT-PCR. 
Dengue** Chikungunya** Zika 
















































Serum specimen should be tested by: 
 Zika MAC-ELISA 
 a dengue IgM assay** 
If any IgM assay yields positive or equivocal 
results for a specimen, results must be 
confirmed by PRNT. 
All tests negative.  




Serum tested by CDC or CDC-designated 
Confirmatory Testing Lab. 
Combine PRNT results with results of other 
diagnostic tests to determine overall 
interpretation. See table on p. 8. 
One or both tests 
positive or equivocal. 
Forward for 
confirmation by PRNT 
NOTE:  Report all test results.  Results should be considered in the context of symptoms, exposure risk and 
time point. 
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2016 Zika Response: Algorithm for U.S. Testing of Symptomatic Individuals* 
Specimens Collected ≥ 14 Days Following Symptom Onset  
 
 
NOTE:  Report all test results.  Results should be considered in the context of symptoms, exposure risk and time point. 
*Pregnant and non-pregnant symptomatic individuals 
**For CDC guidance on patient management and follow-up for dengue or chikungunya virus infection, please refer to 
the CDC websites listed on p. 9 of this document. 
Serum and Urine Specimens Received 
(possibly with CSF or amniotic fluid) 
Test serum (and CSF, if submitted) by Serological Methods 
Serum specimen should be tested by: 
 ZIKA MAC-ELISA 
 a dengue IgM assay** 
 a chikungunya IgM assay** 
If any IgM assay yields positive or equivocal results for a specimen, and 
rRT-PCR is negative for all specimens, results must be confirmed by PRNT. 
All tests negative.  




Serum tested by CDC or CDC-
designated confirmatory 
testing lab. 
Combine PRNT results with 
results of other diagnostic 
tests to determine overall 
interpretation.  
See table on p. 8. 
Dengue or chikungunya IgM 
positive or equivocal. 
Forward for confirmation by 
PRNT 
Patient is pregnant 
 
Test serum and urine (and 
amniotic fluid, if 
submitted) by rRT-PCR for 
ZIKV only 









All specimens negative, 
patient negative for Zika 
virus RNA. 
Forward anti-Zika IgM 
positive specimen for 
confirmation by PRNT 
 
Patient is not pregnant 
 
Forward for confirmation 
by PRNT 
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2016 Zika Response: Algorithm for U.S. Testing of Asymptomatic Pregnant Women 
Serum and Urine from Asymptomatic Pregnant Women Meeting Epidemiologic Criteria 
 
Serum and urine received 
Specimens collected <14 days after return from travel or exposure  Specimens collected 2-12 weeks after return from travel or exposure 
or from women living in areas with ongoing Zika transmission 
 
Test serum and urine by rRT-PCR for ZIKV only Test serum by Zika MAC-ELISA 
 
Zika MAC-ELISA negative.  
No further testing of specimen 
required. 
PRNT 
Serum tested by CDC or CDC-designated confirmatory testing lab. 
Report results.  Combine results with results of other diagnostic tests to 
determine overall interpretation. See table on p. 8. 
Test serum and urine by rRT-PCR for ZIKV only 
Zika MAC-ELISA positive or 
equivocal. 
Test serum and urine by rRT-PCR 
Either specimen positive, 




Both negative, patient negative for Zika virus RNA. 
Forward serum for confirmation of Zika MAC-ELISA 
by PRNT 
Either specimen positive, 
patient positive for Zika 
virus infection. 
 
Both negative, patient negative for Zika 
virus RNA. 
 Health care provider should request 
collection of a follow-up serum specimen 
2-12 weeks following exposure or return 
from travel. 
Test follow-up serum by Zika MAC-
ELISA. 
Zika MAC-ELISA positive or 
equivocal. 
Forward for confirmation by 
PRNT 
Zika MAC-ELISA negative.  
No further testing of specimen 
required. 
NOTE:  Report all test results.  Results should be considered in the context of exposure risk and time point. 
 
 
